Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity
Abstract
Multiple myeloma (MM) is the second most common hematological malignancy in the US and Europe-comprising approximately 10% of all hematologic cancer cases-and its incidence has increased over the last three decades by approximately 120% due to an aging world population. It remains an incurable cancer among diseases in modern medicine. This review outlines the relevant cancer biology of MM, with a special emphasis on the role of tumor protein p53. We provide the most up-to-date summary of the current drugs in clinical or pre-clinical trials targeting weaknesses in the MM apoptotic mechanism. In addition, we highlight the potential for new routes to strike and kill myeloma cells, possibly creating a vaccine-like effect that prevents relapse, using the principles of immunogenic cell death (ICD).
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Immunotherapy and Immune Responses
PI3K/AKT/mTOR signaling in cancer
Publication details
- Journal / source
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Volume
- 27
- Issue
- 3
- Pages
- 1439–1439
- Publication date
- 31 January 2026
- Language
- EN